Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

NCT06600802 · clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
120
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Centre Jean Perrin

Collaborators